Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools IDH-mutant glioma

IDH-mutant glioma

Programs, trials, and reported response and survival for IDH-mutant glioma.

Data as of 11.07.2026

All studies

Vorasidenib

INDIGO

Servier · Phase 3 · Active, not recruiting · Enrollment 331

NCT04164901

Catalyst Primary completion. 09.06.2022. ClinicalTrials.gov primary completion date. This is a registry date, not a company readout.

ArmReported safety
Vorasidenib 40 mg dailygrade 3 or higher adverse events: 22.8%, NEJM 2023 (placebo 13.5%)grade 3 or 4 ALT increase (pooled): 9%, labelgrade 3 or 4 AST increase (pooled): 4.8%, labelpermanent discontinuation for ALT elevation: 2.9%, label

A count stays a count. This page does not turn a count into a percent.